Trial Details

COMPLETED
Basic Information
Clinical ID c995
Identifier NCT03029143
Trial Title Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

YES
Conditions Colitis, Ulcerative
Interventions DRUG: Vedolizumab IV
Participant Information
Sponsor Takeda
City Tucson
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE4
Time Information
Start Date 2017-03-29
Primary Completion Date 2020-10-16
Completion Date 2020-10-16